Tags

Type your tag names separated by a space and hit enter

Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Vaccine. 2015 Sep 22; 33(39):5110-7.V

Abstract

BACKGROUND

This study describes a double-blinded randomized placebo-controlled phase I clinical trial of A/H5N2 live attenuated influenza vaccine in healthy volunteers.

METHODS

Two doses of vaccine or placebo were administered intranasally to 30 and 10 subjects, respectively. Nasal swabs were examined for vaccine shedding and local antibody responses; serum samples were tested for binding, hemagglutinating and neutralizing antibodies and peripheral blood mononuclear cells were tested for cell-mediated immune responses.

RESULTS

The vaccine was well tolerated and not associated with increased rates of adverse events or the occurrence of serious adverse events. Influenza virus was detected in nasal swabs on the first day in the majority of volunteers (93%), while 17% of volunteers tested positive on the second, none on the third day or later following the first vaccination; lower frequency of shedding was observed after the second vaccination. The vaccine was immunogenic as assessed four weeks after the second dose, with 37.9% and 48.3% of subjects seroconverting by hemagglutination inhibition and neutralization assays, respectively. An immune response was observed in 96.6% subjects that received A/H5N2 LAIV in at least one of the assays conducted. None of the placebo recipients exhibited a response in any of the assays.

CONCLUSION

The A/H5N2 vaccine was safe, well tolerated, and immunogenic in healthy adults.

TRIAL REGISTRATION

ClinicalTrials.gov NCT01719783.

Authors+Show Affiliations

Department of Virology, Institute of Experimental Medicine, 197376 St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, 197376 St Petersburg, Russia. Electronic address: irina.v.kiseleva@mail.ru.Department of Molecular Virology, Institute of Influenza, 197376 St Petersburg, Russia.Department of Epidemiology and Prophylaxis, Institute of Influenza, 197376 St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, 197376 St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, 197376 St Petersburg, Russia.Department of Virology, Institute of Experimental Medicine, 197376 St Petersburg, Russia.Department of Molecular Virology, Institute of Influenza, 197376 St Petersburg, Russia.Department of Biotechnology, Institute of Influenza, 197376 St Petersburg, Russia.PATH, Seattle, WA 98121, USA.No affiliation info available

Pub Type(s)

Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26296497

Citation

Rudenko, Larisa, et al. "Clinical Testing of Pre-pandemic Live Attenuated A/H5N2 Influenza Candidate Vaccine in Adult Volunteers: Results From a Placebo-controlled, Randomized Double-blind Phase I Study." Vaccine, vol. 33, no. 39, 2015, pp. 5110-7.
Rudenko L, Kiseleva I, Stukova M, et al. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. Vaccine. 2015;33(39):5110-7.
Rudenko, L., Kiseleva, I., Stukova, M., Erofeeva, M., Naykhin, A., Donina, S., Larionova, N., Pisareva, M., Krivitskaya, V., & Flores, J. (2015). Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. Vaccine, 33(39), 5110-7. https://doi.org/10.1016/j.vaccine.2015.08.019
Rudenko L, et al. Clinical Testing of Pre-pandemic Live Attenuated A/H5N2 Influenza Candidate Vaccine in Adult Volunteers: Results From a Placebo-controlled, Randomized Double-blind Phase I Study. Vaccine. 2015 Sep 22;33(39):5110-7. PubMed PMID: 26296497.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. AU - Rudenko,Larisa, AU - Kiseleva,Irina, AU - Stukova,Marina, AU - Erofeeva,Marianna, AU - Naykhin,Anatoly, AU - Donina,Svetlana, AU - Larionova,Natalie, AU - Pisareva,Maria, AU - Krivitskaya,Vera, AU - Flores,Jorge, AU - ,, Y1 - 2015/08/19/ PY - 2014/10/24/received PY - 2015/07/27/revised PY - 2015/08/05/accepted PY - 2015/8/23/entrez PY - 2015/8/25/pubmed PY - 2016/6/21/medline KW - A/H5N2 KW - Clinical trial KW - Immune response KW - Influenza KW - Live attenuated influenza vaccine KW - Pre-pandemic vaccine SP - 5110 EP - 7 JF - Vaccine JO - Vaccine VL - 33 IS - 39 N2 - BACKGROUND: This study describes a double-blinded randomized placebo-controlled phase I clinical trial of A/H5N2 live attenuated influenza vaccine in healthy volunteers. METHODS: Two doses of vaccine or placebo were administered intranasally to 30 and 10 subjects, respectively. Nasal swabs were examined for vaccine shedding and local antibody responses; serum samples were tested for binding, hemagglutinating and neutralizing antibodies and peripheral blood mononuclear cells were tested for cell-mediated immune responses. RESULTS: The vaccine was well tolerated and not associated with increased rates of adverse events or the occurrence of serious adverse events. Influenza virus was detected in nasal swabs on the first day in the majority of volunteers (93%), while 17% of volunteers tested positive on the second, none on the third day or later following the first vaccination; lower frequency of shedding was observed after the second vaccination. The vaccine was immunogenic as assessed four weeks after the second dose, with 37.9% and 48.3% of subjects seroconverting by hemagglutination inhibition and neutralization assays, respectively. An immune response was observed in 96.6% subjects that received A/H5N2 LAIV in at least one of the assays conducted. None of the placebo recipients exhibited a response in any of the assays. CONCLUSION: The A/H5N2 vaccine was safe, well tolerated, and immunogenic in healthy adults. TRIAL REGISTRATION: ClinicalTrials.gov NCT01719783. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/26296497/Clinical_testing_of_pre_pandemic_live_attenuated_A/H5N2_influenza_candidate_vaccine_in_adult_volunteers:_results_from_a_placebo_controlled_randomized_double_blind_phase_I_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)01133-0 DB - PRIME DP - Unbound Medicine ER -